Abdominal Migraine

Definition and Classification

• Yamada's Textbook of Gastroenterology, p. 2333
• Adams and Victor's Principles of Neurology, 12th ed., p. 2450

Epidemiology

• Affects 1-4% of children in the United States
• Predominantly a pediatric condition; mean age of onset in children is ~4.2 years
• Also occurs in adults, though under-recognized; mean adult age of onset is ~31 years
• Female-to-male ratio is approximately 1.6:1
• Diagnostic delay averages 3.1 years in children and 4.0 years in adults
• Many affected children eventually transition to typical migraine headaches in adulthood

Pathophysiology

• Serotonergic dysregulation - altered 5-HT signaling in gut-brain axis
• Trigeminovascular activation with central sensitization
• Autonomic nervous system dysfunction (explaining pallor, nausea, vomiting)
• Kynurenine pathway of tryptophan metabolism has been implicated in children (potentially affecting both serotonin and inflammatory mediators)
• The gut-brain axis is central: the pain generator is considered to be the CNS projecting to the abdomen, not primary gut pathology
• Yamada's Textbook of Gastroenterology, p. 2333

Diagnostic Criteria (ICHD-3 / Rome IV)

Clinical Features

• Pain: Midline/periumbilical, dull or "sore" quality, moderate-to-severe intensity
• Nausea: 66% of cases
• Vomiting: 54%
• Headache: 47%
• Pallor: frequent
• Photophobia and anorexia: frequently observed
• Episodes are stereotyped - the same patient tends to have similar attacks each time
• Between attacks, the child is completely well (this is a key feature distinguishing it from organic disease)

Differential Diagnosis

• Cyclic vomiting syndrome (vomiting predominates over pain)
• Abdominal epilepsy (associated with EEG abnormalities, CNS symptoms, responds to anticonvulsants)
• Functional abdominal pain / IBS
• Organic causes: appendicitis, inflammatory bowel disease, pancreatitis, mesenteric lymphadenitis, urinary tract disorders, metabolic disorders (porphyria, diabetic ketoacidosis), Henoch-Schonlein purpura, lead poisoning

• Harriet Lane Handbook, 23rd ed.; Swanson's Family Medicine Review

Adults

• Yamada's Textbook of Gastroenterology, p. 2333
• See also: Abdominal Migraine in Adults: A Narrative Review (2025) (PMID: 40662012)

Management

Acute Treatment

Prophylactic (Preventive) Treatment

Non-Pharmacological

• Identify and avoid triggers (stress, certain foods, sleep disruption, travel)
• Regular sleep, meals, hydration
• CBT and hypnotherapy - best evidence base per current RCT data

Prognosis

• Many children improve as they age
• A significant proportion (~50-60%) develop classical migraine headaches in later childhood or adulthood
• AM itself may remit with time, but migraine equivalents may persist in a different form

Key Takeaways

1. AM is an underdiagnosed cause of recurrent abdominal pain in children (and some adults).
2. Diagnosis is clinical using ICHD-3/Rome IV criteria - exclusion of organic disease is required.
3. The pain is midline/periumbilical, stereotyped, lasts 2-72 hours, with complete recovery between attacks.
4. Headache is absent in over half of cases - do not require it for diagnosis.
5. Triptans are most effective acutely; cyproheptadine and propranolol are common prophylactics.
6. The strongest current RCT evidence supports hypnotherapy and CBT for pediatric abdominal pain-related functional GI disorders including AM.
7. It represents a migraine spectrum disorder - many children will develop typical migraine later.

Platelet Transfusion: Indications

Threshold-Based Indications (Count-Triggered)

Specific Clinical Scenarios

1. Prophylactic (No Active Bleeding)

• Hypoproliferative thrombocytopenia from chemotherapy or bone marrow failure: transfuse at <10,000/µL (AABB strong recommendation)
• Elective central venous catheter placement: transfuse if <20,000/µL
• Elective lumbar puncture: transfuse if <50,000/µL
• Elective major surgery (non-neuraxial): transfuse if <50,000/µL
• Elective neuraxial/CNS/eye surgery: target ≥100,000/µL

2. Therapeutic (Active Bleeding)

• Any patient with active hemorrhage and thrombocytopenia where platelet count is contributing to bleeding
• Target platelet count >50,000/µL for most bleeding situations
• Target >100,000/µL for bleeding in critical spaces (retina, CNS)
• Part of massive transfusion protocol (MTP): 1 unit platelets per 6 units RBC (ratio-based approach in massive hemorrhage)

3. Platelet Dysfunction (Count May Be Normal)

• Post-cardiopulmonary bypass / extracorporeal devices: acquired platelet dysfunction causing microvascular bleeding - platelet count alone is not a reliable guide; transfuse based on clinical bleeding
• Uremia: transfused platelets may not function better than native ones; limited benefit
• Antiplatelet medications (aspirin, clopidogrel): transfusion may help if surgery urgently needed. Note the PATCH trial (RCT) showed platelet transfusions did NOT improve outcomes in aspirin-associated intracranial hemorrhage and were associated with greater morbidity - avoid in spontaneous ICH on aspirin
• von Willebrand disease: anecdotal reports suggest platelets may be adjunctive therapy in resistant bleeding (platelets carry ~10-20% of vWF in α-granules)

4. Pediatric Thresholds (Neonatal/Premature)

Contraindications / When NOT to Transfuse

• Tintinalli's Emergency Medicine, p. 1538; Rosen's Emergency Medicine

Assessing Transfusion Response (Corrected Count Increment)

• Adequate response: CCI ≥7,500 at 1 hour; ≥4,500 at 18-24 hours
• Platelet transfusion refractoriness: CCI <5,000 at 1 hour on two consecutive transfusions
• Causes of poor response: HLA alloimmunization, ABO incompatibility, splenomegaly, active consumption (DIC, sepsis), fever, active bleeding

Product Notes

• Single-donor apheresis platelet unit is standard; raises count by up to 50,000/mm³ in an average adult
• Pooled random donor platelets (6 donors) are available but carry higher risk of disease transmission
• Check platelet count at 1 hour and 24 hours after transfusion - response is variable
• Transfused platelets survive 3-5 days under normal conditions

Recent Guideline Update (2025 ACCP)

• Overall certainty of evidence is very low
• A risk/benefit assessment is mandatory before transfusing in critically ill patients
• Given known risks of transfusion and limited evidence of benefit, most patients benefit from avoiding transfusion
• In patients at high risk or where bleeding would be catastrophic, transfusion should be considered but not reflexively given

AIHA and Platelet Transfusion

1. Platelet transfusion in AIHA - when is it relevant?
2. Evans syndrome - AIHA + immune thrombocytopenia occurring together

Part 1: AIHA Overview

• Harrison's Principles of Internal Medicine, 22nd ed., p. 2858-2870
• Henry's Clinical Diagnosis and Management by Laboratory Methods, p. 896-905

Part 2: Evans Syndrome - AIHA + ITP

• Warm AIHA (immune destruction of RBCs), AND
• Immune Thrombocytopenic Purpura / ITP (immune destruction of platelets)

Key Features

• Henry's Clinical Diagnosis, p. 903; Harrison's Principles, p. 2860

Associated Conditions to Screen For

• SLE (commonest)
• Antiphospholipid antibody syndrome
• ALPS (in children/young adults)
• Common variable immune deficiency (CVID)
• Hodgkin lymphoma / other lymphoproliferative disorders

Part 3: Platelet Transfusion in AIHA / Evans Syndrome

Is Platelet Transfusion Needed in Pure AIHA?

• Splenic sequestration - hypersplenism from increased RBC destruction sequesters platelets
• Evans syndrome - concurrent immune platelet destruction

Platelet Transfusion in Evans Syndrome (Immune Thrombocytopenia Component)

• Tintinalli's Emergency Medicine, Table 238-3
• Rosen's Emergency Medicine

When Platelet Transfusion May Be Used in Evans Syndrome

Part 4: Red Cell Transfusion in AIHA (The Main Transfusion Challenge)

• Severe acute AIHA can be a medical emergency
• Most or all cross-matched units may be serologically incompatible due to circulating autoantibodies
• If life-threatening anemia: it is correct (though paradoxical) to transfuse ABO-matched but incompatible blood - transfused RBCs will be destroyed no faster than the patient's own, but the patient survives in the interim
• Transfusion threshold: Hb <5-6 g/dL with cardiovascular compromise (not a fixed threshold - clinical judgment required)
• Avoid transfusion if anemia is not immediately life-threatening - start prednisone 1 mg/kg/day first
• Each transfused unit may worsen alloimmunization and compatibility problems
• Harrison's Principles, p. 2888-2890; Harriet Lane Handbook, p. 475

Part 5: Treatment of AIHA / Evans Syndrome (Hierarchy)

• Harrison's Principles; Goldman-Cecil Medicine; Mulholland & Greenfield's Surgery

Summary Table

Key take-home: In Evans syndrome, platelet transfusion is a bridge - it is not a treatment. The immune destruction continues until immunosuppression takes effect. Treat the immune process (steroids, rituximab) as the definitive approach. Use platelet transfusion only to prevent catastrophic hemorrhage while awaiting immunotherapy response.

SLE Patient with Platelets 15,000 - Is Platelet Transfusion Okay?

Short Answer

Why Not?

Transfused platelets are coated by the same circulating anti-platelet antibodies and destroyed just as rapidly as the patient's own platelets. The transfusion provides no sustained benefit and does not address the underlying immune mechanism.

What a Count of 15,000 Means Clinically

• Rosen's Emergency Medicine

Correct Management for SLE + Platelets 15,000

Step 1 - Assess for active bleeding first

Step 2 - Immunotherapy (the real treatment)

• Rosen's Emergency Medicine, p. 5031; Firestein & Kelley's Textbook of Rheumatology

The ONE Exception: When Platelet Transfusion IS Used

• Give platelet transfusion at 2-3× normal dose (because rapid destruction is expected)
• Simultaneously give IV methylprednisolone + IVIG to suppress antibody activity
• Understand it is a temporizing bridge - effect lasts only hours
• Consult hematology urgently

"On the rare occasion that a patient with immune thrombocytopenia develops life-threatening hemorrhage, administer an immediate single-donor platelet transfusion (two to three times normal dose), along with IV methylprednisolone and IV immunoglobulin." - Tintinalli's Emergency Medicine

Bottom Line

Acute Pancreatitis: Management Guidelines

Step 1: Diagnosis and Initial Assessment

Diagnostic Criteria (any 2 of 3)

1. Characteristic abdominal pain (epigastric, radiating to back)
2. Serum amylase or lipase ≥3× upper limit of normal
3. Imaging findings consistent with acute pancreatitis (CT/MRI)

Immediate Work-up

• Labs: CBC, BMP (BUN, creatinine), LFTs, serum lipase/amylase, triglycerides, calcium, CRP, blood glucose, coagulation
• Imaging: Abdominal ultrasound is the first imaging modality - assess for gallstones, CBD dilation, pericholecystic fluid
• CT abdomen (contrast-enhanced): NOT required at presentation; indicated if diagnosis is uncertain, clinical deterioration occurs, organ failure develops, or signs of sepsis appear (typically after 72 hours for optimal necrosis assessment)

Step 2: Severity Stratification

Revised Atlanta Classification

Severity Scoring Tools

• B - BUN >25 mg/dL
• I - Impaired mental status (GCS <15)
• S - SIRS (≥2 criteria)
• A - Age >60 years
• P - Pleural effusion on imaging

• Cardiovascular: SBP <90 mmHg or HR >130
• Pulmonary: PaO₂ <60 mmHg
• Renal: Creatinine >2.0 mg/dL

• Harrison's Principles of Internal Medicine, 22nd ed.

Step 3: Fluid Resuscitation (Most Critical Intervention)

A rising BUN during hospitalization = inadequate hydration AND is independently associated with higher in-hospital mortality. A falling hematocrit + falling BUN within 12-24h = adequate resuscitation.

• Harrison's Principles, p. 2791

Step 4: Analgesia

• IV opioid analgesics are standard for pain control (morphine, hydromorphone, fentanyl)
• Hydromorphone and fentanyl are preferred over meperidine (risk of normeperidine toxicity)
• No evidence that morphine worsens pancreatitis (the old concern about sphincter of Oddi spasm is not clinically significant)
• NSAIDs may be used in mild disease

Step 5: Nutrition

Early EN reduces infectious complications, preserves gut mucosal barrier, reduces bacterial translocation, and improves outcomes vs TPN. - ACG Guidelines 2024

Step 6: Antibiotics

The default position is no antibiotics unless there is confirmed infection. Fever and leukocytosis alone in the first week of AP are usually from SIRS, not infection.

Step 7: Management Based on Etiology

Gallstone Pancreatitis

• ERCP is indicated within 24 hours if concurrent acute cholangitis is present
• ERCP within 72 hours for severe gallstone pancreatitis OR biliary obstruction (jaundice, dilated CBD)
• ERCP is NOT indicated in mild gallstone pancreatitis without biliary obstruction - it does not improve outcomes
• Cholecystectomy: should be performed during the same admission in mild gallstone pancreatitis (or within 2 weeks) to prevent recurrence (30-50% recurrence risk if not done)
• In severe pancreatitis: defer cholecystectomy until full recovery

Hypertriglyceridemia-Induced Pancreatitis (TG >1000 mg/dL)

• Insulin infusion, plasmapheresis (in severe cases) to rapidly lower TG
• Long-term: fibrates, omega-3s, dietary fat restriction

Alcohol-Induced Pancreatitis

• Alcohol cessation counseling; address withdrawal

Step 8: ICU Admission and Monitoring

• Persistent SIRS at 24h
• BISAP ≥3
• Elevated admission BUN + hematocrit not responding to fluids
• Any evidence of organ failure (respiratory, cardiovascular, renal)
• Hemodynamic instability

• Invasive hemodynamic monitoring (CVP, arterial line)
• Hourly urine output
• Blood gases, CBC, metabolic panel every 8-12h
• Blood glucose (stress hyperglycemia - insulin as needed)
• Serum calcium (hypocalcemia = poor prognosis)

Step 9: Management of Local Complications

Local Complication Classification (Revised Atlanta)

Sterile Necrosis

• Conservative management in most cases
• Wait 4-6 weeks to allow collections to organize and "wall off" before intervention
• Only intervene if causing symptoms (gastric outlet obstruction, biliary obstruction, pain)

Infected Necrosis (Definitive Treatment = Step-Up Approach)

1. Antibiotics (broad-spectrum, IV)
         ↓ (if no improvement in 48-72h)
2. Minimally invasive drainage:
   - Endoscopic transmural drainage (EUS-guided) - preferred if WON adjacent to stomach/duodenum
   - Percutaneous catheter drainage (CT-guided)
         ↓ (if no improvement)
3. Necrosectomy:
   - Direct endoscopic necrosectomy (DEN)
   - Video-assisted retroperitoneal debridement (VARD)
   - Surgical transgastric necrosectomy
         ↓ (last resort)
4. Open surgical necrosectomy

• Percutaneous drainage alone is sufficient in ~33-50% of infected necrosis cases
• Antibiotics alone (without drainage) can be sufficient in ~65% of patients
• Open necrosectomy reserved for failure of minimally invasive approaches

"A step-up approach involves percutaneous or endoscopic drainage followed by minimally invasive or endoscopic necrosectomy for patients who do not improve." - Current Surgical Therapy 14e

Pseudocyst

• Most resolve spontaneously
• <10% of patients have persistent fluid collections at 4 weeks meeting pseudocyst criteria
• Intervention only for symptomatic collections (pain, obstruction, infection)
• Method: endoscopic transmural drainage preferred over surgery

Step 10: Discharge Criteria and Follow-Up

• Pain controlled on oral analgesics
• Tolerating oral diet
• No fever, stable vitals
• No pending interventions required
• Cholecystectomy (for gallstone AP) planned or completed
• Follow-up imaging at 4-6 weeks if necrosis or collections present
• Evaluate for exocrine pancreatic insufficiency (especially in necrotizing AP) and new-onset diabetes

Summary Quick Reference

Most Recent Guidelines

• ACG 2024 Guidelines on Acute Pancreatitis (PMID: 38857482) - emphasis on early refeeding, LR fluids, ERCP only in cholangitis
• IAP/APA/EPC/IPC/JPS Revised Guidelines 2025 (PMID: 40651900) - 96 questions across 18 domains; GRADE-based; covers pregnancy, trauma, metabolic AP; largest international consensus to date

Ranson's Criteria - Complete Calculation Guide

Version 1: Non-Gallstone (Alcoholic) Pancreatitis

AT ADMISSION (5 criteria)

AT 48 HOURS (6 criteria)

Version 2: Gallstone (Biliary) Pancreatitis

AT ADMISSION (5 criteria)

AT 48 HOURS (5 criteria - NOTE: only 5, no PO₂)

Note: Arterial PO₂ is NOT included in the gallstone version.

Scoring Interpretation

• <3 = Mild, uncomplicated disease likely
• ≥3 = Severe pancreatitis (meets criteria)
• >6 = Mortality risk ~50%

Memory Mnemonics

Non-Gallstone Admission (GA LAW):

• G - Glucose >200
• A - Age >55
• L - LDH >350
• A - AST >250
• W - WBC >16,000

48-Hour (C HOBF):

• C - Calcium <8
• H - Hematocrit fall >10
• O - O₂ (PaO₂) <60
• B - BUN rise >5
• F - Fluid sequestration >6L
• + Base deficit >4

Important Limitations

"The Ranson score has a low positive predictive value (50%) and high negative predictive value (90%). Therefore, it is mainly used to rule out severe pancreatitis or predict risk of mortality." - Sabiston Textbook of Surgery

Quick Comparison: Scoring Systems

• Schwartz's Principles of Surgery, 11th ed., Table 33-7
• Sabiston Textbook of Surgery, Box 92.1-92.2